AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03549065 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brain Stimulation
Description: Transcranial magnetic stimulation (TMS) is a minimally invasive brain stimulation method that stimulates the brain of an individual focally(George \& Belmaker, 2007). TMS pulses that are delivered repetitively and rhythmically are referred to as repetitive TMS (rTMS).~Transcranial direct current stimulation (tDCS) is another form of non-invasive brain stimulation that is being investigated as an intervention for neurological and psychiatric disorders. A weak direct electrical current (0-2 mA) flows between two small electrodes via saline soaked sponges placed on the scalp (Nitsche MA et al, 2008).
Study NCT03549065 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Brain Stimulation
Description: Transcranial magnetic stimulation (TMS) is a minimally invasive brain stimulation method that stimulates the brain of an individual focally(George \& Belmaker, 2007). TMS pulses that are delivered repetitively and rhythmically are referred to as repetitive TMS (rTMS).~Transcranial direct current stimulation (tDCS) is another form of non-invasive brain stimulation that is being investigated as an intervention for neurological and psychiatric disorders. A weak direct electrical current (0-2 mA) flows between two small electrodes via saline soaked sponges placed on the scalp (Nitsche MA et al, 2008).
Study NCT00253370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 43-9006
Description: Given orally
Study NCT00253370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT00253370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT01634568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V81444
Description: Single ascending oral doses of V81444 and placebo~Multiple ascending oral doses of V81444 and placebo
Study NCT02483494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APN-led Telemedicine
Description: Allocation to experimental or Usual care is 1:1.~The four study APNs will be delivering the care and have at least three years working experiences in coronary care settings. A telephonic script and study protocol is made available to ensure standardization of intervention.
Study NCT01308996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INFUSE® Bone Graft
Description: Implantation of INFUSE® Bone Graft \[recombinant human Bone Morphogenetic Protein-2 (rhBMP-2)\] and absorbable collagen sponge (ACS) carrier at 1.50 mg/cc with space maintenance device
Study NCT01308996 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone graft from tibia or iliac crest
Description: Implantation of autogenous bone graft from iliac crest or tibia with titanium mesh space maintenance device
Study NCT01010204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomly assigned to receive either varenicline or placebo for 12 weeks. Patients assigned to varenicline will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study, i.e. 11 weeks. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline. Patients will be instructed to take study medication after meals with a glass of water.
Study NCT00919945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous feeding at time 1 and NPO at time 2
Description: Continuous nasogastric formula feeding (using Enfalac with iron 2400 kJ/L at a volume of 1ml/kg/h) at time 1 and NPO at time 2 (12 hours later)
Study NCT00919945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NPO at time 1 and continuous feeding at time 2
Description: NPO at time 1 and continuous nasogastric formula feeding (using Enfalac with iron 2400 kJ/L at a volume of 1ml/kg/h) at time 2 (12 hours later).
Study NCT03186586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate
Description: 5mg/day/five days
Study NCT03186586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one pill a day for 5 days at the bleeding episode
Study NCT00535938 — intervention group
Intervention type: OTHER
Intervention: botulinum toxin type A
Description: There will be no protocol-mandated intervention with regard to physician treatment choice or management of patient condition once the patient is enrolled in the project.
Study NCT03457974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saliva
Description: salivary secretion rate, salivary buffering capacity, pH, protein levels, superoxide dismutase (SOD), ferric reducing antioxidant power (FRAP), the thiobarbituric acid reactive substances (TBARS), protein carbonyl, protein thiols, total sialic acid.
Study NCT03457974 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: saliva
Description: salivary secretion rate, salivary buffering capacity, pH, protein levels, superoxide dismutase (SOD), ferric reducing antioxidant power (FRAP), the thiobarbituric acid reactive substances (TBARS), protein carbonyl, protein thiols, total sialic acid.
Study NCT04136600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR antibody and Chemotherapy
Description: Drug: Cetuximab Cetuximab: 500 mg/m2 iv on Day 1 of cycle every 3 weeks, until disease progression.~Other Names:~Erbitux Drug: Nimotuzumab Nimotuzumab: 400mg iv on Day 1 of cycle, every week, until disease progression~Drug: Fluoropyrimidine 5-fluorouracil (5-FU): 2,400 mg/m2/day iv in first 46 hours of cycle, every two weeks for 12 cycles~Other Names:~5-Fu Drug: Capecitabine Capecitabine: 1000 mg/m2 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~Xeloda Drug: S-1 S-1: 60mg for BSA>1.5, 50 mg for 1.5>BSA>1.25 , 40mg for BSA\<1.25 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~S-1 Drug: Oxaliplatin Oxaliplatin: 85 mg/m2 iv on Day 1 of cycle, every 2 week for 12 cycles with 5-Fu; Oxaplatin: 130 mg/m2 iv on Day 1 of cycle, every 3 week for 6 cycles combined with S-1 or Capecitabine;
Study NCT04136600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: Drug: Fluoropyrimidine 5-fluorouracil (5-FU): 2,400 mg/m2/day iv in first 46 hours of cycle, every two weeks for 12 cycles~Other Names:~5-Fu Drug: Capecitabine Capecitabine: 1000 mg/m2 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~Xeloda Drug: S-1 S-1: 60mg for BSA>1.5, 50 mg for 1.5>BSA>1.25 , 40mg for BSA\<1.25 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~S-1 Drug: Oxaliplatin Oxaliplatin: 85 mg/m2 iv on Day 1 of cycle, every 2 week for 12 cycles with 5-Fu; Oxaplatin: 130 mg/m2 iv on Day 1 of cycle, every 3 week for 6 cycles combined with S-1 or Capecitabine;
Study NCT03310671 — intervention group
Intervention type: PROCEDURE
Intervention: Echocardiogram
Description: Conventional transthoracic echocardiogram by an echocardiographer trained to perform and centered on aortic valve~Pick up from:~* Mean transvalvular pressure gradient~* Aortic valve~* Aortic valve opening area~* Aortic valve opening area adjusted for body mass index~* Bicuspid or tricuspid aorta~* Thickness of the upper valve> 3 mm
Study NCT01646528 — intervention group
Intervention type: PROCEDURE
Intervention: CLE examination for upper gastrointestinal tract
Description: Routine upper GI endoscopy plus targeted CLE examination
Study NCT01517607 — intervention group
Intervention type: OTHER
Intervention: Mesalazine
Description: Patient's treated with oral Mesalazine
Study NCT04601597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shu Bei Kang (China) Midline Catheters
Description: The procedures ① evaluation and selection of blood vessels: select the puncture vein in the middle of the patient's upper arm, ② Skin disinfection and towel laying: take the supine position, extend the upper limb to be punctured 45 \~ 90 °, disinfect the pre punctured upper limb with 75% alcohol and 5% povidone iodine. ③ Puncture vein: tie a tourniquet to fill the vein. Before puncture, use 0.2 \~ 0.4 ml of 2% lidocaine for local anesthesia. Under the guidance of ultrasound, use the puncture needle in the improved sedinger assembly for puncture. After successful puncture, insert the guide wire. ④ Delivery and confirmation of catheter position: after successful puncture, insert the dilator catheter sheath assembly, withdraw the setinger guide wire, deliver the catheter, after catheter placement, flush and seal the catheter with normal saline, and fix the catheter with sterile dressing.
Study NCT02274077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXPAREL
Study NCT02274077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study NCT00988533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Ivermectin Cream
Description: Topical 0.5% ivermectin cream applied to scalp and hair on day 1
Study NCT00943722 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503
Description: Multivalent HPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lots 1, 2, or 3.
Study NCT03993457 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Escitalopram
Description: Escitalopram will be started at 5 mg/day during the first week of treatment. The dose will then be increased to 10mg/day, and can be increased to 20 mg/day. Dose can be decreased to 5 mg by clinician discretion such as to increase tolerability or better manage side-effects. 5 mg will be the lowest dose allowed in the study.
Study NCT03993457 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bupropion
Description: Bupropion-XL will be started at 150 mg/day and increased to 300 mg/day after one week. This dose can be increased to 450 mg/day (divided in 2 doses) at Week 2 or later. Clinicians may opt to titrate bupropion-XL in a slower fashion in cases that might increase tolerability or better manage side-effects. 150 mg will be the lowest dose allowed in the study.
Study NCT01117129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1000 mg by i.v. infusion on day 1 and 15
Study NCT01117129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: i.v. infusion on day 1 and 15
Study NCT01117129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 10-25 mg weekly
Study NCT01117129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate
Description: 10-25 mg weekly
Study NCT01117129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [Mabthera/Rituxan]
Description: 1000 mg by i.v. infusion on day 1 and 15, 2nd and further cycles in patients with (group A) or without (group B) clinical response in cycle 1
Study NCT01117129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rituximab [Mabthera/Rituxan]
Description: 1000 mg by i.v. infusion on day 1 and 15, 2nd and further cycles in patients with (group A) or without (group B) clinical response in cycle 1
Study NCT03939481 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: Given chemotherapy regimen
Study NCT03939481 — intervention group
Intervention type: OTHER
Intervention: Functional Assessment
Description: Functional and sensory clinician assessments
Study NCT03939481 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Patient and physician reported responses
Study NCT03182296 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 68Ga-NODAGA-exendin-4 PET/CT
Description: 68Ga-NODAGA-exendin-4 PET/CT
Study NCT03182296 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-exendin-4 PET/CT
Description: 68Ga-NODAGA-exendin-4 PET/CT
Study NCT04902599 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renuvion/j-Plasma procedure using blunt dissection technique
Description: Renuvion/j-Plasma procedure using blunt dissection technique
Study NCT04902599 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renuvion/j-Plasma procedure using ultrasound-guided dissection technique
Description: Renuvion/j-Plasma procedure using ultrasound-guided dissection technique.
Study NCT03701633 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Postpartum ultrasound
Description: Measurements of the UtA doppler ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.
Study NCT01852188 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Type of glove used for intrapartum vaginal exams
Description: Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
Study NCT03234712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-321
Description: Intravenous infusion
Study NCT01441583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RAAT
Description: For Pacemaker and CRT-P: Right Atrial Automatic Threshold (RAAT)
Study NCT01441583 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RAAT
Description: For Pacemaker and CRT-P: Right Atrial Automatic Threshold (RAAT)
Study NCT01441583 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RYTHMIQ
Description: For pacemakers only: RYTHMIQ RYTHMIQ randomized to on at pre-discharge or at 1-month, depending on assignment
Study NCT03082898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indego Exoskeleton
Description: Regular dosing of Indego Exoskeleton walking.
Study NCT04517968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immediate implant with customized healing abutment
Description: * All patients will be operated under local anesthesia.~* Atraumatic extraction of the remaining root or tooth will be achieved.~* A careful curettage of the socket will be performed if any granulation tissue is present.~* Sequential drilling of the osteotomy site with copious irrigation will be done~* The Implant is secured in place using a torque wrench.~* Fabrication of the customized abutment with flowable composite by first placing a rubber dam between the abutment and the implant to prevent leakage of composite into the socket then start adding the composite in a manner to seal the socket.~* Finishing the composite outside the patient's mouth will be done to ensure the borders are smooth with no sharp ends.~* The abutment will be attached to the implant.
Study NCT02080390 — intervention group
Intervention type: PROCEDURE
Intervention: Transthoracic echocardiogram (ultrasound)
Description: Any transthoracic echocardiogram (ultrasound) of the heart, performed as part of standard clinical care, will be further evaluated for special parameters that may help to detect weakening.
Study NCT01688817 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physician's counseling
Description: Colorectal cancer (CRC) screening was recommended to a patient personally by a PCP. The issue was discussed during a routine medical visit according to a standardized scheme. PCP provided a patient with a rationale for CRC screening in asymptomatic individuals and benefits of early treatment of the disease. A patient was told about colonoscopy-based screening program. A PCP provided patient with information on how colonoscopy is performed and how to prepare a bowel for the examination, and informed a patient about possible adverse events related to the procedure including post-polypectomy bleeding and bowel perforation. According to the scheme of the discussion screening modalities other than colonoscopy were not debated, unless a patient specifically asked about them.
Study NCT01688817 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information leaflet
Description: Patients were given leaflet on primary colonoscopy colorectal cancer screening program. A leaflet provided rationale for colorectal cancer screening and information on colonoscopy-based colorectal cancer screening program.
Study NCT02449057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUST
Description: Swift, certain, and proportionate sanctions for violations of terms of community supervision.
Study NCT04211025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modest
Description: The modest intervention consists of a 30-minute appointment (by phone or in-person) with the designated staff using the Benefits Screening Tool , and a plan is developed. At 4 weeks, the designated staff follows-up with a phone call or email.
Study NCT04211025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive
Description: The intensive intervention consists of a 30-minute appointment with the designated staff using the Benefits Screening Tool , and a plan is developed. At 4 weeks, a follow-up appointment is booked for 30 minutes, and progress on the plan is assessed. At 12 weeks after the initial meeting, the designated staff follows-up with a phone call or email.
Study NCT05656612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written, Oral and Visual Education
Description: Before the training, state anxiety levels were measured with a questionnaire. The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale.
Study NCT05656612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written, Oral and Visual Education
Description: Before the initial training was given, state anxiety levels were measured with a questionnaire.~The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale.
Study NCT00559377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-fluoromisonidazole
Description: Undergo \^18F FMISO PET scan
Study NCT00559377 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorodeoxyglucose F 18
Description: Undergo \^18F FDG PET scan
Study NCT00559377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo \^18F-FMISO and \^18F FDG PET scan
Study NCT00559377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tissue oxygen measurement
Description: Undergo \^18 F FMISO PET and \^18F FDG PET
Study NCT02020746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EscharEx
Study NCT02020746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gel Vehicle
Study NCT05142579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDOTRAKEAL TUBE HOLDER
Description: During this process, the tube detection of endotracheal tube holder was changed every 24 hours, and the tubes were repositioned every 4 hours. On the first day of the study, the oral mucosa of patients in this group was evaluated by the eliers oral evaluation guide.Then, with the Braden pressure wound risk diagnostic scale, patients ' Pressure Wound risk assessment was performed. Patients in this group were monitored for four days for oral pressure wound as of the day they were intubated. During this process, patients ' tube holder was changed every 24 hours and the tube was repositioned every 4 hours. At the end of the fourth day, wound evaluation of patients who developed pressure wounds was performed using the international pressure wound staging system and pressure ulcer Recovery Assessment Scale. In addition, pressure wounds of patients who developed pressure wounds were treated in accordance with the recommendation of a plastic surgeon.
Study NCT05142579 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BANDAGE
Description: On the first day of the study, the oral mucosa of patients in this group was evaluated by the eliers oral evaluation guide.Then, with the Braden pressure wound risk diagnostic scale, patients ' Pressure Wound risk assessment was performed. Patients in this group were monitored for four days for oral pressure wound as of the day they were intubated. During this process, patients ' tube holder was changed every 24 hours and the tube was repositioned every 4 hours. At the end of the fourth day, wound evaluation of patients who developed pressure wounds was performed using the international pressure wound staging system and pressure ulcer Recovery Assessment Scale.In addition, pressure wounds of patients who developed pressure wounds were treated in accordance with the recommendation of a plastic surgeon.
Study NCT02205294 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Treatment
Description: The osteopathic treatment will be a gentle hands treatment using myofascial release techniques.
Study NCT01734590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate based food mix 1
Description: Carbohydrate based food
Study NCT01734590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate based food mix 1
Description: Carbohydrate based food
Study NCT01734590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate based food mix 2
Description: Carbohydrate based food
Study NCT01734590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate based food mix 2
Description: Carbohydrate based food
Study NCT01734590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control carbohydrate based food
Description: Carbohydrate based food
Study NCT02867800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: (Standard of Care) Premedication~Diphenhydramine: 1 mg/kg IV or PO q 8 hours (maximum=50 mg)
Study NCT02867800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: (Standard of Care) Premedication~Acetaminophen: 10-15 mg/kg PO q 6 hours (maximum=1000 mg)
Study NCT02867800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: (Standard of Care) Premedication~Methylprednisolone: 0.25-0.5 mg/kg IV q 6 hours